You just read:

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

News provided by

Eli Lilly and Company; Incyte Corporation

Dec 09, 2014, 07:00 ET